Bonsignore A, Bragazzi NL, Basile C, Pelosi P, Gratarola A, Bonatti G, Patroniti N, Ciliberti R Development and Validation of a Questionnaire investigating the Knowledge, Attitudes and Practices of Healthcare Workers in the Field of Anesthesiology concerning the Italian Law on Advance Healthcare Directives: a Pilot Study. Acta Biomed. 2021 Sep 2;92(4):e2021092. doi: 10.23750/abm.v92i4.11314.
Ciliberti R, Gorini I, Gazzaniga V, De Stefano F, Gulino M The Italian law on informed consent and advance directives: New rules of conduct for the autonomy of doctors and patients in end-of-life care. J Crit Care. 2018 Dec;48:178-182. doi: 10.1016/j.jcrc.2018.08.039. Epub 2018 Aug 29.
Graw JA, Marsch F, Spies CD, Francis RCE End-of-Life Decision-Making in Intensive Care Ten Years after a Law on Advance Directives in Germany. Medicina (Kaunas). 2021 Sep 4;57(9):930. doi: 10.3390/medicina57090930.
Le Dorze M, Kandelman S, Veber B; SFAR's Ethics Committee End-of-life care in the French ICU: Impact of Claeys-Leonetti law on decision to withhold or withdraw life-supportive therapy. Anaesth Crit Care Pain Med. 2019 Dec;38(6):569-570. doi: 10.1016/j.accpm.2019.10.013. No abstract available.
Leemans K, Deliens L, Van den Block L, Vander Stichele R, Francke AL, Cohen J Systematic Quality Monitoring For Specialized Palliative Care Services: Development of a Minimal Set of Quality Indicators for Palliative Care Study (QPAC). Am J Hosp Palliat Care. 2017 Jul;34(6):532-546. doi: 10.1177/1049909116642174. Epub 2016 Apr 7.
Mentzelopoulos SD, Couper K, Raffay V, Djakow J, Bossaert L Evolution of European Resuscitation and End-of-Life Practices from 2015 to 2019: A Survey-Based Comparative Evaluation. J Clin Med. 2022 Jul 11;11(14):4005. doi: 10.3390/jcm11144005.
Mercadante S, Gregoretti C, Cortegiani A Palliative care in intensive care units: why, where, what, who, when, how. BMC Anesthesiol. 2018 Aug 16;18(1):106. doi: 10.1186/s12871-018-0574-9.
Riessen R, Bantlin C, Wiesing U, Haap M [End-of life decisions in intensive care units. Influence of patient wishes on therapeutic decision making]. Med Klin Intensivmed Notfmed. 2013 Jun;108(5):412-8. doi: 10.1007/s00063-013-0233-3. Epub 2013 Mar 17. German.
Strauss S, Kuppinger D, Hartl WH [Quality of dying processes after commencement of the German Living Will Act : Experiences of a surgical intensive care unit]. Chirurg. 2017 Mar;88(3):244-250. doi: 10.1007/s00104-016-0345-4. Erratum In: Chirurg. 2017 Mar;88(3):251-252. German.
Virdun C, Luckett T, Lorenz K, Davidson PM, Phillips J Dying in the hospital setting: A meta-synthesis identifying the elements of end-of-life care that patients and their families describe as being important. Palliat Med. 2017 Jul;31(7):587-601. doi: 10.1177/0269216316673547. Epub 2016 Dec 8.
Vitale C, de Nonneville A, Fichaux M, Salas S Medical staff opposition to a deep and continuous palliative sedation request under Claeys-Leonetti law. BMC Palliat Care. 2019 Jan 8;18(1):2. doi: 10.1186/s12904-018-0384-3.
Vuong C, Kittelson S, McCullough L, Yingwei Y, Hartjes T Implementing primary palliative care best practices in critical care with the Care and Communication Bundle. BMJ Open Qual. 2019 Sep 6;8(3):e000513. doi: 10.1136/bmjoq-2018-000513. eCollection 2019.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.